SCNLF (Scancell Holdings) Cash Flow for Dividends: $0.00 Mil (TTM As of Oct. 2025)


SCNLF Scancell Holdings PLC SCNLF
20 GF Score
Price $0.28
! 2 Warning Signs
View Full Analysis

What is Scancell Holdings Cash Flow for Dividends?

Scancell Holdings SCNLF 20 Cash Flow for Dividends is $0.00 Mil as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Scancell Holdings's cash flow for dividends for the six months ended in Oct. 2025 was $0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Oct. 2025 was $0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Scancell Holdings Cash Flow for Dividends Related Terms

Scancell Holdings Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Scancell Holdings's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scancell Holdings Cash Flow for Dividends Chart

Scancell Holdings Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Scancell Holdings Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24 Oct24 Apr25 Oct25
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SCNLF
20GF Score
Scancell Holdings PLC SCNLF
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scancell Holdings Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Oct. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of $0.00 Mil mean?
Scancell Holdings (SCNLF) has a Cash Flow for Dividends of $0.00 Mil as of Oct. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Scancell Holdings and its competitors.
Is Scancell Holdings' Cash Flow for Dividends too high?
Scancell Holdings' current Cash Flow for Dividends is $0.00 Mil. Overall, Scancell Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' Cash Flow for Dividends compare to VRTX and REGN?
Scancell Holdings' Cash Flow for Dividends of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Scancell Holdings and its competitors. Scancell Holdings's current Cash Flow for Dividends is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current Cash Flow for Dividends of $0.00 Mil. The current Cash Flow for Dividends is $0.00 Mil. Scancell Holdings' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current Cash Flow for Dividends is $0.00 Mil as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scancell Holdings Business Description

Other Exchanges SCLP:UKSCP:Germany
Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
20GF Score

Get the complete analysis for SCNLF

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price